Arbutus Biopharma (US.ABUS)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.ABUS · 同比： 2026 Q1 vs 2025 Q1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | 65.2% | ↑ |
| Cash Conversion | -4.8% | → |
| D/E Ratio | 0.00 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.ABUS (Arbutus Biopharma) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE 65.2% ↑ Cash Conversion -4.8% → D/E Ratio 0.00 ↑ Gross Margin 0.0% ↓
核心指标
US.ABUS (Arbutus Biopharma) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE 65.2% ↑Cash Conversion -4.8% →D/E Ratio 0.00 ↑Gross Margin 0.0% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies